0.60Open0.77Pre Close3 Volume43 Open Interest1.50Strike Price180.00Turnover328.82%IV-4.17%PremiumAug 16, 2024Expiry Date0.64Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6271Delta0.5688Gamma1.15Leverage Ratio-0.0062Theta-0.0006Rho-0.72Eff Leverage0.0008Vega
Sangamo Therapeutics Stock Discussion
please fly to moon, make my day.
This treatment for patients with hemophilia A appears to have the efficacy and safety metrics in place to warrant a potential approval.
Notably, Sangamo’s candidate is being developed alongside $Pfizer(PFE.US)$ , adding a layer of clout to the R&D behind the prospective treatment.
woke up at 3.55am just to ensure no more position.. fall asleep earlier.. small profit still a profit.. not a fan of holding stock.need peace…
No comment yet